share_log

bluebird bio | NT 10-K: Others

bluebird bio | NT 10-K: Others

bluebird bio | NT 10-K：其他
SEC announcement ·  03/26 06:59
Moomoo AI 已提取核心信息
bluebird bio, Inc. has announced that it will delay the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The company cited the identification of certain accounting errors related to U.S. GAAP applications in contracts with manufacturing organizations as the reason for the delay. These errors have led to the need to restate financial statements for the year ended December 31, 2022, and for the first three quarters of both 2022 and 2023. The restatement process requires additional time, preventing the company from meeting the April 1, 2024, filing deadline. bluebird bio also disclosed a material weakness in its internal control over financial reporting, which has resulted in ineffective disclosure controls and procedures. The company is currently evaluating its internal controls and will provide a remediation plan in the forthcoming 2023 Form 10-K. Despite the restatements, bluebird bio does not anticipate any impact on its cash position or revenue. The company has communicated that it expects to file the delayed report by the fifteenth calendar day following the original due date.
bluebird bio, Inc. has announced that it will delay the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The company cited the identification of certain accounting errors related to U.S. GAAP applications in contracts with manufacturing organizations as the reason for the delay. These errors have led to the need to restate financial statements for the year ended December 31, 2022, and for the first three quarters of both 2022 and 2023. The restatement process requires additional time, preventing the company from meeting the April 1, 2024, filing deadline. bluebird bio also disclosed a material weakness in its internal control over financial reporting, which has resulted in ineffective disclosure controls and procedures. The company is currently evaluating its internal controls and will provide a remediation plan in the forthcoming 2023 Form 10-K. Despite the restatements, bluebird bio does not anticipate any impact on its cash position or revenue. The company has communicated that it expects to file the delayed report by the fifteenth calendar day following the original due date.
蓝鸟生物公司宣布，它将推迟提交截至2023年12月31日财年的10-K表年度报告。该公司指出，延迟的原因是与制造组织签订的合同中发现了与美国公认会计原则申请有关的某些会计错误。这些错误导致需要重报截至2022年12月31日的年度以及2022年和2023年前三个季度的财务报表。重报过程需要更多时间，这使公司无法在2024年4月1日的申报截止日期之前完成。蓝鸟生物还披露了其财务报告的内部控制存在重大缺陷，这导致披露控制和程序失效。该公司目前正在评估其内部控制措施，并将在即将发布的2023年10-K表格中提供补救计划。尽管进行了重报，但蓝鸟生物预计不会对其现金状况或收入产生任何影响。该公司已表示，预计将在原定到期日后的第十五个日历日之前提交延迟报告。
蓝鸟生物公司宣布，它将推迟提交截至2023年12月31日财年的10-K表年度报告。该公司指出，延迟的原因是与制造组织签订的合同中发现了与美国公认会计原则申请有关的某些会计错误。这些错误导致需要重报截至2022年12月31日的年度以及2022年和2023年前三个季度的财务报表。重报过程需要更多时间，这使公司无法在2024年4月1日的申报截止日期之前完成。蓝鸟生物还披露了其财务报告的内部控制存在重大缺陷，这导致披露控制和程序失效。该公司目前正在评估其内部控制措施，并将在即将发布的2023年10-K表格中提供补救计划。尽管进行了重报，但蓝鸟生物预计不会对其现金状况或收入产生任何影响。该公司已表示，预计将在原定到期日后的第十五个日历日之前提交延迟报告。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息